The main targets for hematological malignancy include CD19, CD22, CD33, and CD7 for relapsed and refractory leukemia and lymphoma (NCT01974479, NCT02742727, NCT02892695, NCT02944162, NCT03056339, NCT03579927, NCT03690310, NCT03692767, and NCT03824951) and B-cell maturation antigen for multiple myeloma (NCT03940833). The gene discussed is CD19; the disease is leukemia.